Expired Canadian patentCanada
A transgenic coagulation factor xiii defective animal and its use for testing wound healing and bleeding
CA 2282721 C · Owner: Csl Behring Gmbh · Inventors: Zettlmeissl, Gerd; Grundmann, Ulrich; Li, Meng
Overview
Drawings and full text
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides a transgenic non-human mammalian animal which is heterozygous or homozygous for an at least partially defective coagulation factor XIII gene.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 21, 1999 and granted March 27, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 21, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 21, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledSeptember 21, 1999
GrantedMarch 27, 2012
Term endedSeptember 21, 2019
Patent numberCA 2282721 C
Classification (IPC)C12N15/12 +2 more
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.